Compare Summit Therapeutics Inc (SMMT) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B). The key difference: Summit Therapeutics Inc is far larger — about 3.5× Direxion Daily TSLA Bull 2X Shares's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| SMMT | TSLL | |
|---|---|---|
Market Cap | $13.71B | $3.97B |
Volume | 6,173,057 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.38 | $23.03 |
52-Week Low | $12.43 | $6.74 |
Typical Hold Time | 16 Days | 15 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
TSLL, a leveraged ETF tracking Tesla, trades at $10.01, down 1.38% amid neutral technical signals. Moving averages suggest a bullish trend, but RSI indicates overbought conditions. The ETF lacks traditional financial ratios due to its structure, and recent news highlights its volatility tied to Tesla's Cybercab event.
Outlook hinges on Tesla's performance, offering amplified gains but high risk from daily rebalancing. Investors face significant volatility and potential decay, requiring careful risk management given the leveraged nature and dependence on Tesla's stock movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
